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Background: The conventional osteosarcoma (OS) is the commonest primary malignant, bone tumor with complex
genomic profiles and poor survival. Runt-related transcription factor 2 (RUNX2) and WW domain containing
oxidoreductase (WWOX) genes are implicated in normal osteogenesis as well as in the development of primary
conventional OS.
Methods: We retrospectively assessed protein and RNA expression of the RUNX2 and WWOX genes by quantitative
real time PCR (qPCR) and immunohistochemistry (IHC) in 80 cases of primary OS and 20 normal control (NC)
subjects. Proteins and RNA expression levels of both genes were correlated to clinico-pathological features of the
patients, progression free and overall survival (PFS& OS) rates.
Results: In OS, RUNX2 protein was detected in 72/80 (90%) cases compared to 4/20 (20%) NC samples (p. < 0.001)
and RUNX2-RNA was up regulated (up to 103.2 folds) in 60/80 (75%) (p = 0.01). WWOX protein and RNA (up to 7.2
folds) were detected in all NC samples but in 24/80 (30%) and 20/80 (20%) OS cases; respectively (p. < 0.001 for
each). The concordance between the RNA and protein expressions for RUNX2 and WWOX was significantly high
(X_trend^2 = 6.33; p = 0.012 and X_trend^2 = 19, p < 0.001; respectively). A significant inverse relation existed
between RUNX2 and WWOX RNA and protein (p = 0.032, p = 0.008). There was significant correlation between
RUNX2 RNA/protein, high tumor grade and stage (p = <0.001; each); RUNX2 RNA and male gender, tumor site
and metastasis (p = 0.007, 0.041, 0.003; respectively). WWOX protein associated significantly with advanced stage
and metastasis (p = 0.001& 0.024; respectively) and WWOX RNA associated with metastasis (p = 0.003).
Conclusions: RUNX2 and WWOX play opposing roles in the development and progression of OS. They could
be used as sensitive prognostic biomarkers for OS patients and RUNX2 represents a promising candidate for
targeted therapy.
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Osteosarcoma (OS) is the most common primary malig-
nant, non-hematopoietic, bone tumor worldwide. It rep-
resents 55% of childhood and adolescent malignant bone
tumors in the United States [1, 2]. According to the
National Cancer Institute Registry in Egypt, OS repre-
sents the most common primary malignant bone tumor
in constituting 47.75%, of the cases followed by Ewing’s
sarcoma (17.57%), chondrosarcoma (14.86%) and Non-
Hodgkin lymphoma (9.01%) (NCI) [3]. It is also one of
the significant causes of morbidity and mortality, espe-
cially in the young age group [1]. The etiology of OS is
not well known yet and the tumors are usually heteroge-
neous with complex genomic aberrations and rearrange-
ments. In spite of the recent improvements in the
treatment modalities of OS including neoadjuvant or ad-
juvant chemotherapy and radiotherapy, the 5 year-sur-
vival is still poor (25–30%), especially for patients with
metastasis, [4, 5]. Therefore, Studying the molecular
pathogenesis of OS is highly required for better under-
standing of tumor biology, to identify molecular prog-
nostic and predictive biomarkers as well as for better
selection of genes that could be used as candidates for
targeted therapy [6, 7].
The Runt-related transcription factor 2 (RUNX2) and
the WW domain containing oxidoreductase (WWOX)
are two important genes that have recently been linked
to the development and progression of OS [8, 9].
RUNX2 gene is located at chromosome 6p12-2. It is one
of the transcriptional regulators of osteogenesis, it is
responsible for the terminal osteoblastic differentiation
and it also triggers the expression of major bone matrix
protein genes during the early phase of osteoblastic
differentiation [10, 11]. It has been shown that, the
RUNX2 protein exerts its oncogenic effects through
regulation of various genes and pathways which are
implicated in tumorigenesis, especially in the regulation
of apoptosis [12]. Overexpression of RUNX2-RNA and
protein were detected in OS cases, as well as in many
other tumor types with poor prognostic impact [7, 9].
The WWOX gene occupies an active fragile site
(FRA16D) which is located at the 16q23.3 ± 24.1 region.
It codes for a protein, which contains two N-terminal
WW domains and a central short-chain dehydrogenase/
reductase domain [13]. The WWOX protein plays an
important role in the maturation of osteoprogenitor cells
and in regulating their proliferation during bone devel-
opment [14]. WWOX is considered a tumor suppressor
gene, which is involved in the regulation of apoptosis
and the interaction between the neoplastic cells and the
extracellular matrix [15, 16]. Therefore, loss of WWOX
expression as a consequence of genetic and epigenetic
aberrations has been associated with poor prognosis and
an aggressive phenotype in many tumor types [13].The interplay between RUNX2 and WWOX genes was
previously highlighted. It was found that the contribu-
tion of WWOX gene to bone formation is partially re-
lated to its regulation of RUNX2 activity [17]. Moreover,
during the pathogenesis of tumors, WWOX gene exerts
its regulatory effect on the signaling network through
the interaction of its first WW protein domain with
some transcription factors and signal transduction
proteins including RUNX2, p73, Ap2α, Ap2γ and ErbB4
[18, 19]. Therefore, we sought to assess, the contribution
of aberrant RUNX2 and WWOX genes expressions to
the development and progression of conventional OS in
a group of patients from Egypt through correlating their
RNA and protein expression levels to the standard
clinic-pathological prognostic factors, response to treat-
ment and survival rates.
Methods
Patients and tissue specimens
Formalin-fixed paraffin-embedded (FFPE) tissue blocks
for 80 well-characterized conventional OS patients who
were diagnosed and treated in the National Cancer
Institute (NCI), Cairo University and the Faculty of
Medicine, Alexandria University Hospitals, during the
period from 2008 to 2013 were collected from the Surgical
Pathology Departments of the two centers. Cases were se-
lected according to the following criteria: 1) treatment
naive patients with no previous neoadjuvant chemo-
therapy 2) adequacy of representative tumor tissues in
the tumor blocks and 3) the availability of relevant clinico-
pathological and follow up data of the patients. All cases
were diagnosed, graded and staged according to the
WHO criteria for grading and staging of OS [20]. Twenty
five, FFPE tissue blocks of normal bone biopsies, obtained
from non-pathologically fractured bones matched for the
age and sex with the OS patients, were also included in
the study as a control group (CG). The most representa-
tive paraffin blocks were identified, hematoxylin and
eosin- stained slides for the tumor samples were examined
microscopically to confirm the diagnosis, determine the
tumor: normal tissues ratio and to choose the proper
tumor block. Only cases with >75% representative neo-
plastic cells in the sections were included in the study to
avoid the neutralizing effect of a high non-neoplastic
component in tumor sections. From each representative
paraffin block, 4 μm thick sections (two sections) were cut
onto positive charged slides and used for the assessment
of RUNX2 and WWOX proteins expression by IHC and
another 5 μm thick sections (7 sections) were cut into a
sterile, plastic, 2 ml Eppindorff tube for RNA extraction
and quantitative real time polymerase chain reaction
(qPCR). Relevant clinico-pathological and follow-up data
of the patients were obtained from the patients’ records in
the Clinical Oncology and the Nuclear Medicine
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NCI, Cairo, Egypt. The ethical committees of the two
Centers approved the study protocol, which was per-
formed according to the 2011 Declaration of Helsinki.2-Management of patients
Pretreatment assessment of the OS patients included
complete medical history, physical examination and histo-
logical examination of hematoxylin and eosin- stained
slides from the tumor masses. Further assessment in-
cluded ECOG performance status, lactate dehydrogenase
(LDH), alkaline phosphatase (ALP), complete blood count
(CBC) with differential and full biochemical panel, includ-
ing liver and renal function tests. Radiological evaluation
included local MRI of the primary and a computerized
tomography (CT) scan of the chest. Additional radio-
logical imaging such as bone scan was done when indi-
cated and imaging was repeated every 6 weeks during
treatment in the neoadjuvant or metastatic settings.
Evaluation was carried out according to modified RECIST
criteria every 6 weeks (in case of metastatic disease). Post-
treatment evaluation and follow up included medical his-
tory and physical examination, CBC and chemistry with
local MRI of the primary and CT chest every 3 months.
The standard treatment for all OS patients included wide
excision or metastasectomy for operable cases with first
line neoadjuvant/adjuvant chemotherapy using either
Cisplatin 100 mg/m2 IV D1/Doxorubicin 25 mg/m2/day
D1-D3 every 21 days for up to 6 cycles or Doxoruici/
Cisplatin/Holoxan/high dose Methotrexate. Second line
therapy was given to relapsed, refractory or metastatic pa-
tients using IV Gemcitabine 675 mg/m2 (Days 1 and 8)
and Docetaxel 75-100 mg/m2 IV (Day 8) every 3 weeks
for up to 13 cycles (median 4 cycles). Post operative radio-
therapy (RT) was considered in patients with unresectable
disease (60–70 Gy) or in patients with positive resection
margins (55Gy with 9–13 Gy boost to microscopic or
gross disease).3-Immunohistochemistry (IHC)
Avidin-Biotin-Peroxidase Complex (ABC) methodology
was used. Briefly, the slides were de-paraffinized in
xylene followed by rehydration in a series of graded
ethanol. Endogenous peroxidase was blocked with 0.3%
H2O2 and retrieval was performed with 10 mM citrate
buffer pH6.0. Tissue sections were incubated overnight
at 4 °C, in a humid chamber, with the primary mouse
monoclonal RUNX2 antibody (27-K, sc-101145, Santa Cruz
Biotechnology, Inc., USA, dilution 1:50); and the rabbit
polyclonal anti-WWOX antibody (ab33248, Abcam Inc.,
USA, dilution 1:100). The reaction was visualized by the
UltraVision Detection System, Thermo Scientific, USA and
the sections were then counterstained with Hematoxylin.Negative and positive controls (placenta for RUNX2 and
skin forWWOX) were included in each run [21].
4- Scoring of IHC results
Slides were examined microscopically using Leica micro-
scope (TC Lab, NCI). The expression levels of RUNX2
(nuclear) and WWOX (cytoplasmic) proteins were evalu-
ated using a scoring system based on the staining intensity
score multiplied by the staining extent score. The extent
of staining was determined according to the percent-
age of stained cells as follows: 0% positively- stained
cells (score 0), 1–10% (score 1), >10–25% (score 2), >25–
50% (score 3), >50–75% (score 4) and >75% positively-
stained cells (score 5). The staining intensity was scored as
follows: no staining (0), mild (1), moderate (2) and intense
(score 3). For statistical purposes, the final scores were
categorized into two groups: negative (0–1) and positive
(2–15) [22].
5-RNA extraction and quantitative real-time PCR (qPCR)
The total RNA was extracted from the tumor and the
normal tissues sections using the RNeasy Mini Kit
(Qiagen, Milan, Italy) and the quality of the extracted
RNA was assessed by spectrophotometry. RNA was dis-
solved in diethyl pyrocarbonate-treated water containing
10 mmol/l of MgCl2 and incubated with 100 μg/ml of
RNase-free DNaseI for 30 min at 37 °C to eliminate the
contaminating DNA. The reaction was stopped by heat-
ing at 95 °C for 5 min after the addition of EDTA to a
final concentration of 30 mmol/l and then RNA was
retro-transcribed using iScriptTM cDNA Synthesis Kit
(Bio-Rad, Milano, Italy). The qRT-PCR analysis was per-
formed in a final volume of 25 μl with a SYBR Green
PCR Master Mix using 1 μl cDNA and 400 nM of prede-
signed RUNX2 primer (Hs_RUNX2_1_SG QuantiTect pri-
mer assay (249900), Qiagen, Hilden, Germany) for RUNX2
gene in stratagene MAX3000P (Applied Biosystems, Inc.,
Foster City, CA, USA). For WWOX gene, TaqMan PCR
Master Mix using Rotor- gene Q (Qiagen, Hilden,
Germany) was used with 1 μl cDNA and 400 nM of
predesigned WWOX hydrolysis probe (Hs_WWOX_QF_1
QuantiFast probe assay (243132), Qiagen, Hilden, Germany).
All steps were done according to manufacturer’s instruc-
tions. For all tumor and normal bone samples, the qPCR
assays were carried out in triplicates.
6-Interpretation of the qPCR results
the mean cycle threshold (CT value) was calculated and
used to determine the delta CT (ΔCT) for each sample
as follows: ΔCT = CT for the gene of interest-CT of the
internal control gene (GADPH). Then the delta delta CT
(ΔΔCT) was calculated as follows: ΔΔCT = (ΔCT for
sample A - ΔCT for sample B), where sample A is the
tumor and sample B is the calibrator (normal bone). For
Table 1 The relation between WWOX (protein and RNA)
expressions and the clinicopathological features of the patients
Clinical features Aberrant WWOX expression
Reduced or lost protein
(56)b
Reduced or lost RNA
(60)c
No. (%) P. value No. (%) P value
Gender
Males (52) 40 (76.9) 38 (73.1) 0.588
Females (28) 16 (57.1) 0.066 22 (78.6)
Age (median)
< 21 years (40) 32 (80) 30 (50) 1.0
≥ 21 years (40) 24 (60) 0.051 30 (50)
Site
Femur (48) 34 (70.8) 35 (72.9)
Tibia (20) 12 (60) 0.371 15 (75) 0.571
Humerus (12) 10 (83.3) 10 (83.3)
Tumor Grade
2 (16) 9 (56.3) 10 (62.5)
3 (64) 47 (73.4) 0.180 50 (78.1) 0.197
pTNM Stage
I, II (44) 24 (54.5) 0.001 32 (72.7) 0.604
III, IV (36) 32 (88.9) 28 (77.8)
Metastasis
Present (20) 18 (90) 0.024a 20 (100) 0.003
Absent (60) 38 (63.3) 40 (66.7)
aSignificant $Borderline significance (using intensity score)
bNormal WWOX protein expression: 24 cNormal WWOX RNA expression: 20
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data were expressed as relative expression units [23].
7-Statistical analysis
Data were analyzed using the statistical package for social
science (SPSS 20). Qualitative data were described using
number and percent, the association was tested using Chi-
square test; if more than 20% of the cells have expected
count less than 5; correction was conducted using Firsher’s
Exact test or Monte Carlo correction. The distributions of
quantitative variables were tested for normality using
Kolmogorov-Smirnov test, which revealed significant devi-
ation from normality, and described using mean, median
and standard deviation (SD). Mann-Whitney (U) and
Kruskal-Wallis (H) tests were used to compare between
two groups and more than two groups respectively.
Spearman’s rho (ρ) correlation was used to test the relation
between quantitative or qualitative ordinal variables. Sig-
nificance test results were quoted as two-tailed probabil-
ities, and judged at the 5% level. Association of relevant
clinico-pathological data, RUNX2 and WWOX expressions
with progression free survival (PFS) or OS was analyzed
using the log-rank test, Kaplan–Meier plot, and Cox pro-
portional hazards regression models. p < 0.05 was consid-
ered statistically significant. The multivariate analysis
included clinicopathologic factors that had p < 0.10.
Results
Clinicopathological data of the patients
The ages of the patients ranged from 15 to 57 years
(median: 21 years), 52 were males and 28 were females
(M:F ratio = 1.9:1), all of them were chemotherapy-naïve.
In the control group (CG), the ages ranged from 17 to
60 years (median: 19 years) with M: F ratio 2:1. Relevant
clinicopathological features of the patients are illustrated
in Tables 1 and 2.
RUNX2 and WWOX protein expressions
The expression levels of WWOX and RUNX2 in normal
bones are illustrated in Fig. 1. In the OS group, 72 (90%)
out of the 80 cases assessed were positive for RUNX2
protein overexpression with a median staining score of 13
(Min.-Max. = 0–15, 95% CI = 53.3, 100) compared to 4/20
cases only (20%) for the control group (95% CI = 70, 100)
with a median staining score of 5 (Min.-Max. = 0–8). The
difference in the expression level of RUNX2 protein be-
tween cases and control subjects was statistically signifi-
cant (U = 3.5, p. < 0.001) (Fig. 2a-c). On the other hand,
WWOX protein expression was detected in all the control
samples (100%; 95% CI = 0, 100) with a median staining
score of 7 (Min.-Max. = 4–10) but in 24/80 (30%) OS
cases only. Fifty six cases showed either reduced or/lost
WWOX protein expression (70%) (95% CI = 54.5, 100).
The median staining score for OS cases was zero(Min.-Max. = 0–6) (Fig. 3a-c). The difference between
patients and control groups was statistically significant
(U = 3.5, p. < 0.001). A significantly negative correlation
was present between WWOX and RUNX2 protein expres-
sions (U = -0.578, p = 0.008).RUNX2 and WWOX-RNA expression
RUNX2-RNA expression was up-regulated (up to 103.2
folds) in 64/80 (80%) OS cases compared to 3/20 (15%) of
the control group (p < 0.001) (Fig. 2d-f). WWOX gene
RNA expression was down-regulated (reduced or lost) in
60/80 (75%) cases and up-regulated in 20 cases (25%, up
to 7.2 folds, 95% CI = 54.5,100) (Figs. 3 and 4). The con-
cordance in the results of RNA and protein expressions
for both genes was significantly high (6.33; p. = 0.012 and
19; p. < 0.001, respectively). The difference between OS
patients and the control group for both genes, was statisti-
cally significant (p. < 0.01). The concordance between
RNA and protein expressions for RUNX2 and WWOX
was significantly high (X_trend^2 = 6.33; p = 0.012 and
X_trend^2 = 19, p < 0.001; respectively).
Table 2 The relation between RUNX2 (protein and RNA)
expressions and the clinicopathological features of the patients





No. (%) P value No. (%) P value
Gender
Males (52) 48 (92.3) 44 (84.6)
Females (28) 24 (85.7) 0.348 16 (57.1) 0.007
Age (median)
< 21 years (40) 40 (100) 32 (80)
≥ 21 years (40) 32 (80) 0.005 28 (70) 0.302
Site
Femur (48) 44 (91.7) 36 (75)
Tibia (20) 16 (80) 12 (60)
Humerus (12) 12 (100) 0.232 12 (100) 0.041
Tumor Grade
2 (16) 8 (50) 4 (25)
3 (64) 64 (100) <0.001* 56 (87.5) <0.001*
pTNM Stage
I, II (44) 36 (81.8) 24 (54.5)
III, IV (36) 36 (100) 0.007 36 (100) <0.001*
Metastasis
Present (20) 20 (100) 20 (100)
Absent (60) 52 (86.7) 0.085$ 40 (66.7) 0.003
*Significant $Borderline significance (using intensity score)
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expression
Significant correlations were found between increased
RUNX2 expression (RNA and protein) and high tumor
grade (p. = 0.032), between RUNX2 RNA and the TNM
stage (p. = 0.01), as well as between RUNX2 protein and
high incidence of metastasis using the intensity scoring
system (p. = 0.02). WWOX-RNA expression correlated sig-
nificantly with high tumor grade and the incidence of me-
tastasis (p = 0.032), whereas WWOX- protein correlated
significantly with the incidence of metastasis (p. = 0.04). AFig. 1 Protein expression of a RUNX2 and b WWOX in normal boney tissueborderline significance was present between WWOX-
protein expression and the grade of the tumor (p. = 0.05)
(Tables 1 and 2).
5-Survival correlations
During the follow up period (range = 18–72 months,
M = 45 months, SD = 38.18), 32 patients (20%) showed
local recurrence, 40 (25%) showed distant metastasis, and
32 (20%) patients succumbed to the disease (relapsed). The
PFS time ranged from 6 to 72 months with an estimated
mean survival time of 56 months (95% CI = 46.6, 65.4) and
the overall survival ranged from 20 to 96 months with an
estimated mean survival time of 72 months (95% CI = 46.6,
65.4). Kaplan–Meier plots showed that OS associated
significantly with RUNX2 protein&RNA overexpres-
sion (p = 0.01), aberrant WWOX expression (protein&
RNA, p = 0.03), pTNM stage and metastasis (p = 0.026 &
p = 0.023; respectively-Fig. 4). Progression free survival
associated significantly with RUNX2-overexpression, high
pTNM stage and the incidence of metastasis (p < 0.01
for all).
Discussion
Although the roles of WWOX and RUNX2 in OS have
been previously addressed, the novelty in this work is with
the assessment of these two genes in Egyptian patients
who have a different ethnicity from US based patients and
therefore they might show different results. Thus, this
work extends the repertoire of studies on RUNX2 and
WWOX in OS. We assessed the prevalence of RUNX2 and
WWOX genes in conventional OS cases from Egypt and
their contribution to patients’ outcome. Previous studies
have shown that both genes contribute to normal bone
metabolism as well as to tumorigenesis and prognosis of
different tumor types including OS. Thus, both genes
could be used as prognostic biomarkers for OS [6, 8, 9].
The data reported in the current study show marked ele-
vation of RUNX2 RNA and protein in OS patients com-
pared to normal control (75 & 90%) whereas WWOX
showed significant reduction at both the RNA and the
protein levels (80%) compared to the normal control.s assessed by immunohistochemistry (X400)
Fig. 2 Cases of osteosarcoma showing a negative immunostaining of RUNX2 in normal bony tissue (X400), b a case of OS, grade 2 showing
moderate nuclear immunostaining of RUNX2 (X200), c a case of OS, grade 3 showing marked and diffuse nuclear immunostaining of RUNX2
(X400), d Bar chart showing the frequency of RUNX2 protein expression in OS cases according to groups, e Amplification plots of RUNX2, SYBR
green, MAX3000P (Applied Biosystems, Inc., Foster City, CA, USA), and f Box blot graph showing increased RUNX2 gene and protein expressions in
OS cases
Bahnassy et al. Applied Cancer Research  (2016) 36:4 Page 6 of 9Similar results have been reported in a recent study by
Yang et al. [22] who found that RUNX2 protein and gene
expression were increased in 48.1 and 55% of human OS
cases with a significant loss of WWOX protein and DNA
expressions in 61.1 and 30% of the studied cases;Fig. 3 Protein expression of WWOX showing a normal boney tissue showi
minimal cytoplasmic WWOX expression of moderate intensity (X400), c amplific
d a bar chart showing the frequency of WWOX protein expression in OS cases
and protein expressions in OS casesrespectively using IHC and the comparative genomic
hybridization (GCH) techniques. Sadikovic et al. [24] also
reported significant overexpression of RUNX2-RNA (113
folds) by quantitative real time PCR (qPCR) and Lu et al.
[25] were able to detect RUNX2 RNA overexpression inng positive WWOX immunostaining (X400), b a case of OS with
ation curves of WWOX, TaqMan, Rotor-gene Q (Qiagen, Hilden, Germany),
according to groups, e Box blot graph showing decreased WWOX gene
Fig. 4 Kaplan maeier curves for a OS in relation to RUNX2 expression, b OS in relation to WWOX expression, c OS in relation to pTNM, d OS in
relation to metastasis, e PFS in relation to RUNX2 expression, f PFS in relation to pTNM, g PFS in relation to metastasis
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There is evidence indicating that, the normal function of
RUNX2 in bone is linked to the p53-MDM2 pathway,
which is perturbed in the Li-Fraumeni patients. Therefore,
there is an increased incidence of OS in Li-Fraumeni
families, which is associated with loss of p53 function [26].
This loss of p53 function increases the differentiation-
related accumulation of RUNX2. In contrast to primary or
immortalised osteoblasts, which normally have low RUNX2
levels, loss of p53 correlates with elevated RUNX2 protein
levels in several growth factor independent OS cell lines
[26]. Hence, it is conceivable that loss of p53 function in
OS contributes to the elevated p53 protein levels, which is
observed in OS patient samples harboring 6p12-6p21 gene
amplifications [26]. Therefore, we assessed our studied
cases for p53 mutations (exons 4-9). Although we were able
to detect some mutations in exons 5, 6 and 8; none of these
mutations correlated with RUNX2 expression (data not
shown). On the other hand, Kurek et al. [27] were the first
to demonstrate that theWWOX gene decreases tumorigen-
icity in nude mice in vitro and in vivo. They found that
100% of the WWOX- deficient mice included in their study
developed OS. Their data support our data in this regard.
The concordance, reported in the current study, between
RUNX2 and WWOX genes expression (at the protein and
RNA levels) has been previously reported by Aqeilan et al.
[17] and Salah et al. [15], though other investigators failed
to find any correlation between WWOX- RNA and protein
in their studies [22, 27]. This could be attributed to the
presence of other factors affecting the WWOX protein
expression, such as abnormal mRNA splicing, missing
exon(s), loss of heterozygosity (LOH) or promotor
hypermethylation of WWOX [28]. Reduced expression of
WWOX was also detected in OS samples of post-treatment
metastastectomies more than in the pre-treatment biopsies
suggesting that decreased WWOX levels indicates more
aggressive tumor phenotypes, especially in the metastatic
sites [22]. Genetic and epigenetic alterations of the WWOX
gene were also detected by Yang et al. [22] and Abdeen et
al. [29] in the more aggressive OS cases, especially those
with reduced survival rates and multiple metastases.
In accordance with these data we found that, aberrant
expression levels of WWOX and RUNX2 genes (RNA&
protein) were more common in patients with high grade
and the advanced stage tumors, and in patients having
increased incidence of metastasis. In addition aberrant
expression of RUNX2 and/or WWOX proteins or RNA in
our studied patients associated significantly with reduced
survival rates, either OS or PFS together with the high
tumor grade, advancesd disease stage and metastasis. Our
data confirm previously reported data in literature regard-
ing the prognostic and predictive values of WWOX and
RUNX2 genes. It also suggests that both genes could beused as sensitive biomarkers of aggression in the conven-
tional OS patients.
A recent in vitro and experimental animal study by Del
Mare and Aqeilan, 2015 (14) provided additional evidence
to the human data. In this study, the authors proved that
WWOX is usually inactivated in human OS cases and its
restoration in cultured WWOX-negative OS cells sup-
pressed tumorigenicity and inhibited the metastatic poten-
tial in the NOD-SCID mice. They demonstrated that this is
achieved either through WWOX –related down regulation
of certain genes that are strongly involved in tumor cell mi-
gration and invasion e.g. ezrin, integrin alpha (4&5),
MMP13 and VEGF, or through suppressing RUNX2 trans-
activation, which normally regulates the expression of cell
motility and adhesion genes in the conventional OS (14).
In the current study, we were able to show that RUNX2
overexpression; either at the protein or the RNA levels; is
usually associated with the aggressive tumor types provid-
ing an evidence for the prognostic value of RUNX2 in
conventional OS and confirming previous reports in
literature in this context [24, 30–34]. In this context,
Sadikovic et al. [24] demonstrated that, out of 16 genes
tested in their study, RUNX2 was the only one which was
significantly overexpressed in OS patients who responded
poorly to chemotherapy. Similar results were also reported
by Won et al. [35] who found a significant correlation be-
tween RUNX2 overexpression and the incidence of metas-
tasis in the conventional OS. This is explainable because
RUNX2 normally regulates important pathways, which are
involved in cell adhesions and motility of the mobile OS
cells [34]. In addition, RUNX2 stimulates VEGF promoter
and consequently its protein expression, with subsequent
stimulation of angiogenesis in the tumor leading to migra-
tion and metastasis of the neoplastic cells [36]. Therefore,
RUNX2 and VEGF were considered by Yang et al. [22] as
two synergistic molecules for angiogenesis in OS patients
as well as promising candidates for targeted therapy.
Taken together, these findings confirm the prognostic and
predictive values of RUNX2 in the conventional OS.
Conclusions
Based on the results of the current study and the previ-
ously published data in literature, we conclude that, both
the WWOX and RUNX2 genes play significant and oppos-
ing roles, in the development and progression of the con-
ventional OS in the Egyptian patients. RUNX2 is usually
overexpressed whereas WWOX is usually reduced, mostly
secondary to RUNX2 overexpression. Therefore both
genes could be used as sensitive biomarkers in OS to pre-
dict tumor progression and patients’ outcome. However,
only RUNX2 could be used as a promising targeted ther-
apy in patients who showed resistance to the traditional
therapeutic modalities for OS, though this has to be tested
in a future study.
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